Neeraj Agarwal,
MD
Languages Spoken: English
Dr. Neeraj Agarwal, MD, a Profesor of medicine, is a physician and an investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, he directs the Genitourinary Oncology (GU) Program, the Center of Investigational Therapeutics (CIT), co-leads the Experimental Therapeutic Program (one of the four cancer center support grant programs at the HCI), and serves on the cabinet of the Director of HCI.
Dr. Agarwal has authored more than 200 peer-reviewed articles and book chapters. He has been invited to give talks at several national and international forums, including the National Institute of Health, and the annual meetings of American Society of Clinical Oncology (ASCO), Society of Urology Oncology (SUO), and Kidney Cancer Association (KCA), Brazilian Society of Urology, Spanish Genitourinary Oncology Group (SOGUG), and various National Cancer Institute (NCI) designated comprehensive cancer centers across the country. He serves as a panel member for the NCCN guideline- committees for bladder, and kidney cancer, and as a consultant to the oncology drug advisory committee (ODAC) to the United States Food and Drug Administration (FDA).
Dr. Agarwal is the overall study chair of multiple clinical trials, including two phase III registration trials, multiple phase II and I trials, and eight investigator initiated clinical trials in GU cancers. In addition, he is leading several other clinical trials as one of the steering committee members. Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences (AIIMS) in New Delhi, India, Dr. Agarwal completed a residency in internal medicine, and a fellowship in geriatric medicine, at the University of Iowa. He then completed a hematology-oncology fellowship at the Huntsman Cancer Institute at the University of Utah.
Dr. Agarwal has the prestigious honor of being chosen as one of the five SWOG young investigators in 2009, as the leader of early therapeutics of the SWOG Genitourinary Cancer Scientific leadership Committee in 2010, of receiving the 2009-2010 William D. Odell Young Investigator award, and the 2014 Cancer Clinical Investigator Team Leadership Award from the NCI. In 2018, he was appointed as Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research.
Clinical Locations
Clinic 2B, GU
801-587-4644
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Cancer Center Programs | Experimental Therapeutics |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
May 13, 2020
HUNTSMAN CANCER CENTER
vert thoughtful
UofU Patient
May 11, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
May 09, 2020
HUNTSMAN CANCER CENTER
i enjoyed the experience
UofU Patient
April 19, 2020
HUNTSMAN CANCER CENTER
Dr Agarwal is always sensitive to my needs, very supportive, kind, and provided me with encouragement and support.
UofU Patient
April 18, 2020
HUNTSMAN CANCER CENTER
Every one so great and caring! The Dr. is so kind and so competent. I have total confidence in his skills. Jared, the Nurse Practitioner, is also great. we feel so blessed to have them as our health care providers.
UofU Patient
March 30, 2020
HUNTSMAN CANCER CENTER
Those who met with me were well prepared, and had obviously read my case. Each listened with care and treated me as a whole person.
UofU Patient
March 16, 2020
HUNTSMAN CANCER CENTER
better communications
UofU Patient
March 04, 2020
HUNTSMAN CANCER CENTER
I have nothing but praise for my team at HCI.
UofU Patient
February 15, 2020
HUNTSMAN CANCER CENTER
I hav accepted his advise to sign up for the study.
UofU Patient
February 15, 2020
HUNTSMAN CANCER CENTER
Dr. Agrawal was excellent in his care and concern during this most difficult time. I had my 3 daughters with me and he was attentive to their questions and concerns. A tough but good visit. I have aggresive metastatic castrate resistant prostate cancer
UofU Patient
February 04, 2020
HUNTSMAN CANCER CENTER
I recommend you to everyone I talk to
UofU Patient
January 28, 2020
HUNTSMAN CANCER CENTER
after 3 years, i have never been shown my scans nor shown were my metastic cancers are located specifically. the " my chart" test reports really need to be dumbed down A LOT!
UofU Patient
January 26, 2020
HUNTSMAN CANCER CENTER
Not that kind of visit. It was first visit familiarization and learning about the procedures and treatments plus meeting some of the staff.
UofU Patient
January 15, 2020
HUNTSMAN CANCER CENTER
Dr. Agarwal was in a hurry when he arrived and wanted to process my appointment very quickly and get to a meeting. I give him great credit for recognizing I had a lot of concerns and questions being I was transitioning from radiation oncology to systemic therapy and that no longer was I wondering if my cancer would go into remission, but rather how do I manage the statistically limited time I may be alive. He reworked his morning to stay and answer my questions, explain what may happen to me health wise, and give me very solid, professional care. I truly appreciated his making those changes and being with me during this transition.
UofU Patient
January 07, 2020
HUNTSMAN CANCER CENTER
Very Very Good
UofU Patient
December 28, 2019
HUNTSMAN CANCER CENTER
Julia Baten is an asset to the team. I feel comfortable with her and I can discuss anything with her
UofU Patient
December 22, 2019
HUNTSMAN CANCER CENTER
goot
UofU Patient
December 15, 2019
HUNTSMAN CANCER CENTER
We love the care we get from Jerrod and the nurses, and the oversight by Dr. Agarwal.
UofU Patient
December 08, 2019
HUNTSMAN CANCER CENTER
Dr. Agarwal is one of the finest human beings I've ever met - I am so lucky that he is my doctor.
UofU Patient
November 27, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
November 22, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
November 19, 2019
HUNTSMAN CANCER CENTER
Dr. Agarwall spent most of the time discussing the clinical trial option.
UofU Patient
November 13, 2019
HUNTSMAN CANCER CENTER
Very good
UofU Patient
November 08, 2019
HUNTSMAN CANCER CENTER
awesome
UofU Patient
October 28, 2019
HUNTSMAN CANCER CENTER
my team explains my options and my condition in depth and completely.
UofU Patient
October 28, 2019
HUNTSMAN CANCER CENTER
I know exactly where I stand with my Cancer problem, and how pleased they are with my progress toward remission.
UofU Patient
October 12, 2019
HUNTSMAN CANCER CENTER
every consideration was taken to invoke me in ALL recommendations my concerns both emotionally and physically
UofU Patient
September 30, 2019
HUNTSMAN CANCER CENTER
positive
UofU Patient
September 18, 2019
HUNTSMAN CANCER CENTER
saw Dr Agarwal today, that is always a plus for me.
UofU Patient
September 16, 2019
HUNTSMAN CANCER CENTER
Doctor Agarwall spoke with me for a long time assuring me and helping me know that he my best interest in mind and would do his utmost to bring my Cancer under control and into remission ASAP. I really like him, and have much confidence in him
UofU Patient
August 27, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
August 19, 2019
HUNTSMAN CANCER CENTER
Very Professional
UofU Patient
August 12, 2019
HUNTSMAN CANCER CENTER
very positive
UofU Patient
August 05, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
July 30, 2019
HUNTSMAN CANCER CENTER
Dr. Agarwal and his team were extraordinary. During my many visits to Huntsman, I received nothing but exceptional care. The information provided, concern shown, efforts provided by every member of the team, and discussion of treatments was simply outstanding. I will recommend Dr. Agarwal in particular and Huntsman in general without reservation.
UofU Patient
July 28, 2019
HUNTSMAN CANCER CENTER
Don't know what options are available because he didn't really get into that except for a case study. If there are other medicines nothing was mentioned.
UofU Patient
July 20, 2019
HUNTSMAN CANCER CENTER
excellent
UofU Patient
July 19, 2019
HUNTSMAN CANCER CENTER
Good lisrener, explanations were easy to understand
UofU Patient
June 25, 2019
HUNTSMAN CANCER CENTER
GOOD
UofU Patient
June 01, 2019
HUNTSMAN CANCER CENTER
Dr. Agarwal goes out of his way to greet with a smile and handshake. we love him!
UofU Patient
May 28, 2019
HUNTSMAN CANCER CENTER
I recommend all of them to everyone I can. My entire experience with HCI has been extraordinary start to finish.
UofU Patient
May 16, 2019
HUNTSMAN CANCER CENTER
Everyone was amazing.
UofU Patient
May 05, 2019
HUNTSMAN CANCER CENTER
Super doctors, great care. plus the treatment is working
UofU Patient
May 03, 2019
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
April 18, 2019
HUNTSMAN CANCER CENTER
AGAIN, A GREAT EXPERIENCE
UofU Patient
March 25, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
March 21, 2019
HUNTSMAN CANCER CENTER
I recommend HCI all of the time
UofU Patient
March 17, 2019
HUNTSMAN CANCER CENTER
explained the process very well
UofU Patient
March 11, 2019
HUNTSMAN CANCER CENTER
Dr. AGARWAL WAS VERY PROFESSIONAL AND CONCERNED.. HE WAS WELL INFORMED ABOUT ME AND I WAS PLEASED WITH THE CARE AND ATTENTION GIVEN..
UofU Patient
March 10, 2019
HUNTSMAN CANCER CENTER
Always a good experience at Huntsman
UofU Patient
February 28, 2019
HUNTSMAN CANCER CENTER
It was the care, concern and efficiency of the scheduler that I talked to the very first time I called that convinced me that I had called the right place. And I have continued to receive that kind of treatment ever since!
UofU Patient
February 27, 2019
HUNTSMAN CANCER CENTER
Dr Agarwal and his staff are the best
UofU Patient
February 19, 2019
HUNTSMAN CANCER CENTER
Julia Batton provides the best care.
UofU Patient
February 18, 2019
HUNTSMAN CANCER CENTER
Outstanding as always
UofU Patient
February 07, 2019
HUNTSMAN CANCER CENTER
love Dr N Agarwal & his team - very confident in my care
UofU Patient
February 02, 2019
HUNTSMAN CANCER CENTER
We have had many good experiences over the last few years. Great people, they are very knowledgeable and concerned about us.
UofU Patient
December 24, 2018
HUNTSMAN CANCER CENTER
I refer EVERYONE to HCI
UofU Patient
December 01, 2018
HUNTSMAN CANCER CENTER
excellent
UofU Patient
December 01, 2018
HUNTSMAN CANCER CENTER
We LOVE Dr. Agarwal. Myhusband and Iare so blessed to have him as our caretaker. he is absolutely the best!
UofU Patient
November 03, 2018
HUNTSMAN CANCER CENTER
I asked a question on blood work data and did not receive an answer except "we do not follow that result in our study"
UofU Patient
October 19, 2018
HUNTSMAN CANCER CENTER
informative and productive visit
UofU Patient
October 16, 2018
HUNTSMAN CANCER CENTER
Sometimes I feel as if the Doctor is very rushed - however, I can understand since my results were good, the clinic was very busy and perhaps there were others that were not as fortunate and needed his time more than I.
UofU Patient
October 12, 2018
HUNTSMAN CANCER CENTER
I'm just very upset !
UofU Patient
September 10, 2018
HUNTSMAN CANCER CENTER
they even know me by my name
UofU Patient
September 09, 2018
HUNTSMAN CANCER CENTER
There are lots of things I could say about Dr Agarwal but I will just say he is the best. I love hime like family and have the utmost confidence in his care for me.
UofU Patient
August 29, 2018
HUNTSMAN CANCER CENTER
we are concerned about his psa going up and the dr explained what we can expect in the future.
UofU Patient
August 28, 2018
HUNTSMAN CANCER CENTER
I have from the very beginning recommended Huntsman to everyone that asks!
UofU Patient
August 24, 2018
HUNTSMAN CANCER CENTER
I believe I am receiving a very high level of care. Thank you very much
UofU Patient
August 21, 2018
HUNTSMAN CANCER CENTER
From the very beginning I have been able to recommend my Care Provider without any reservations. In fact when my mother was diagnosed with breast cancer we took her to Doctor Buys for her treatment. She was very kind, patient,and very professional with my mother. After a few treatments her cancer went into remission.
UofU Patient
August 17, 2018
HUNTSMAN CANCER CENTER
Best patient education I have ever seen (APRN) Great personalized service (med tech) Time spent by Dr Agarwal explaining treatment program at Huntsman and his personal commitment to treating prostate cancer exceeded my expectations and gained my confidence.
UofU Patient
August 06, 2018
HUNTSMAN CANCER CENTER
it was a great experience
UofU Patient
August 04, 2018
HUNTSMAN CANCER CENTER
i have all the confidence in my doctors
UofU Patient
July 20, 2018
HUNTSMAN CANCER CENTER
I follow up those 5's by telling EVERYONE (ad nauseam) how wonderful Huntsman is.
UofU Patient
July 07, 2018
HUNTSMAN CANCER CENTER
All the people I deal with are very professional and treat me with respect.
UofU Patient
July 05, 2018
HUNTSMAN CANCER CENTER
very confident about my care!
UofU Patient
June 15, 2018
For four years you have cared for Bob! It's been amazing!
UofU Patient
May 13, 2018
great experience
UofU Patient
April 26, 2018
Detailed explanation of condition and treatment options with good topline of side effects
UofU Patient
April 15, 2018
this was with out a doubt the most informative meetings I have had since comeing to Huntsman Hospital. I wish all sessions were this informative. most are good but I learned more about my cancer today than sat any other time.
UofU Patient
April 10, 2018
We felt blessed by such a dedicated and kind proffessional who gave us his full attention and established confidence and trust.
UofU Patient
March 21, 2018
great
UofU Patient
March 02, 2018
The best care givers.
UofU Patient
February 20, 2018
good
UofU Patient
February 19, 2018
I have all the trust and confidence in Dr. Agarwal and his staff!
UofU Patient
February 16, 2018
I am so confident and pleased with all of the staff when ever I go into the room for a visit.
UofU Patient
February 15, 2018
great
UofU Patient
February 13, 2018
good
UofU Patient
February 05, 2018
We always feel that we are in very capable,caring hands. It was like talking with good friends.
UofU Patient
January 22, 2018
Great staff in all aspects
UofU Patient
January 14, 2018
Dr Agrawal and Dr Tward are excellent physicians.
UofU Patient
December 28, 2017
fabulous and professional treatment
UofU Patient
December 08, 2017
very professional and caring in all aspects
UofU Patient
December 02, 2017
We LOVE Dr. Agarwal as well as his assistant, Julie Battan!
UofU Patient
November 14, 2017
Very Good
UofU Patient
August 25, 2017
Huntsman Cancer Institute is the best and I am very pleased with the treatment
UofU Patient
August 20, 2017
All Care providers I saw were Great !! Dr Agawar was Courteous, informed and Concerned about my condition. I would not hesitate to recommend Huntsman to Anyone.
UofU Patient
August 12, 2017
Caring
UofU Patient
June 05, 2017
Everyone is such a professional.
UofU Patient
May 30, 2017
The doctor was able to quickly assess my situation, including the bone pain I was experiencing , and provided a pharmaceutical solution. The doctor also was concerned with my kidney functioning , which was reflected on my lab results, and ordered an IV to help flush the kidneys.
UofU Patient
May 27, 2017
very caring treatment and explanations
UofU Patient
May 17, 2017
good
UofU Patient
April 28, 2017
A lot of information. Good experience but lots of things going on.
UofU Patient
March 19, 2017
I have the highest confidence in Dr. Agarwal and his staff.
UofU Patient
March 14, 2017
Julia Outstanding !
UofU Patient
March 05, 2017
we wouldn't want anyone else treating _____. Dr. Agarwal is the best!
UofU Patient
February 25, 2017
great personnel
UofU Patient
February 13, 2017
I'm very confident in his watchful care. I know he is making the right decisions for my health. It's always a pleasure to meet with him. I'm grateful that I have Dr. Agarwal for my provider as well as his Staff.
UofU Patient
February 04, 2017
Excellent meeting with the NP!
UofU Patient
January 13, 2017
thankful for the abilities of the Doctors
UofU Patient
December 14, 2016
highly encouraging, willing to cover questions thoroughly, easy to talk with.
UofU Patient
December 12, 2016
We feel very confident with Dr Agarwal.
UofU Patient
October 27, 2016
The Doctor is all ways friendly and helpful with my concerns.
UofU Patient
September 12, 2016
All good.
UofU Patient
September 07, 2016
I always recommend the hospital when I hear of problems involving cancer
UofU Patient
September 04, 2016
all good
UofU Patient
September 01, 2016
In the six years I have been coming here for care Dr. Agarwal and his staff have been the best! I am confident in all they do, I know they sincerely care about me and my cancer and are doing their very best. I know I wouldn't be here without them.
UofU Patient
August 29, 2016
great experience
UofU Patient
August 28, 2016
Doctor Agerwal seemed like he is only interested in himself. It was hard to listen to him because he was yelling. At first I thought he was going to be a good teacher, using the white board, but as time went on I realized he was not interested in answering any of my questions. In fact, it seemed like he was annoyed that I had the nerve to ask any questions. If I asked for him to clarify what he said, he seemed irritated. I have a Master's degree and am no dummy, but am interested in my condition and treatment. He seemed to treat me like I was an imbicile in the way he responded. It seemed like Dr. Agerwal was only interested in getting another body into his trial. He did not indicate from anything he said that he had read any information from my chart. There was no mention of any treatment I had had previously. Dr. Agerwal did not answer any questions about treatment side affects, but said that the pharmacist would do that(the pharmacist never spoke to us or came in). I have 0 confidence in this Doctor. After Dr. Agerwal left, I was told that I did not qualify for the treatment he had just spent an hour and a half yelling about. Why did he waste my time and his telling me about a treatment for which I did not qualify? I will do all I can to avoid going to him again. He did tell me about how much he has been published, and about how much he has done in drug trials and so forth. His "bedside manner " is non existant. The Fellow, Doctor Poole on the other han
UofU Patient
August 26, 2016
provided complete update as to husbands progress and gave us clear direction to follow going forward
UofU Patient
August 25, 2016
Huntsman is the best, they take care of my husband, and family also.
UofU Patient
August 23, 2016
I am starting radiation therapy next month. Huntsman is the only place I will go for treatment!
UofU Patient
August 15, 2016
they all are great clinicians
UofU Patient
August 13, 2016
great care
UofU Patient
August 13, 2016
I think Dr. Agerwal and his PSs are great and tell them so at each appointment.
UofU Patient
June 27, 2016
The degree we have confidence is much higher than 5.
UofU Patient
June 06, 2016
Julia is always great and very informative and concerned when their are questions.
UofU Patient
May 31, 2016
We always receive very personalized care with our providers in this clinic. We appreciate all of them and their skill, concern and effectiveness in helping us each time.
UofU Patient
April 26, 2016
I always receive great service when I go to the Huntsman Cancer Center.
UofU Patient
April 23, 2016
good
UofU Patient
April 19, 2016
Both the PA and Dr. Agarwal were excellent. In fact, the PA was exceptional.
UofU Patient
April 18, 2016
The care level is over the top.
UofU Patient
April 18, 2016
I left feeling that I was in very good hands
UofU Patient
April 04, 2016
My last scans/labs showed a changed in my condition. I feel that he was not ready to discuss it with me. In fact i had to bring it up. During what little conversation we had he got a text and answered it. It felt like he wanted to be somewhere else. I have all the confidence in the world in his abilities, but not a good visit.
UofU Patient
March 31, 2016
Great exp.
UofU Patient
March 09, 2016
He was in a hurry and had other patients to attend to. Seemed upset that I wanted more information. Finally left the room and returned after about 20 or 30 minutes. His English is not easily understood. After he returned, he was less agitated and gave me a little better explanation. During the whole time, my wife and I felt that he talked down to us and treated us as if we were little children who could not understand his explanation. I am trying to decide whether I want to continue on with him.
UofU Patient
March 04, 2016
Very thorough and answered all our questions and offered solutions
UofU Patient
February 20, 2016
Dr. Agarwal spent extra time with us explaining things.
UofU Patient
February 14, 2016
We have already recommended a friend who may be facing prostrate cancer.
UofU Patient
February 13, 2016
It's always the best place to go...............though I freely admit, I wish I didn't have to go there...grin
UofU Patient
January 20, 2016
Providers are always attentive and totally focused on my issues. They never rush through the examination to get to the next patient.
UofU Patient
January 10, 2016
We had and have total confidence in Dr. Agarwal's PA named Julia. She was outstanding.
UofU Patient
January 07, 2016
Great and very professional treatment
UofU Patient
December 13, 2015
good
UofU Patient
December 12, 2015
Dr. Agerwal and staff are amazing, we love and appreciate every one.
UofU Patient
December 10, 2015
I did not understand much the Dr. said, but my wife took good care of explaning for me.
UofU Patient
November 23, 2015
Good
UofU Patient
November 14, 2015
Here the Huntsman Center is unmatchable. Outstanding in every way. I truly feel loved and cared for by Dr. Agarval and his staff. I look forward to seeing them and know, beyond a shadow of a doubt, that everything is fine. I am in the best hands ever. I love them all.
UofU Patient
October 30, 2015
All Good
UofU Patient
October 23, 2015
Absolute confidence!
UofU Patient
October 23, 2015
When my wife ask questions the were answered satisfactory.
UofU Patient
October 20, 2015
As always, our experience with the staff has been wonderful. They are patient with our concerns and questions.
UofU Patient
October 09, 2015
good
UofU Patient
October 04, 2015
Dr. NEERAJ AGARWAL M.D. was extremely helpful and professional.
UofU Patient
September 26, 2015
fortunate to have Dr Agarwal
UofU Patient
September 12, 2015
I love Doctor Agarwal and his staff. I really wouldn't want any other staff caring for me.
UofU Patient
September 08, 2015
He explained my situation in a manner that was easy to understand. His knowledge of my particular case was very good.
UofU Patient
September 03, 2015
Overall it was a good informative experience. I wish now I had come here when first diagnosed.
UofU Patient
August 17, 2015
already have recommended the huntsmen care for others, and from others is where I learned I should go for my own cancer.
UofU Patient
August 07, 2015
I can't think of a better place to help with my cancer and I have already recommended the facility to others
UofU Patient
July 01, 2015
always a good experience. you know what direction you're headed and what to expect. most of all, I recognize I am receiving the best care possible.
UofU Patient
May 11, 2015
Dr Agarwal spent time talking about future treatment without fully explaining the diagnosis. Part of the problem is that he did not take the time to find out what had been explained to me by my previous doctor. He could have asked me, which would have only taken a few minutes, which would have helped him to be much more helpful in explaining both the diagnosis and possible treatment. Also, because my appointment had been changed to 2 days earlier than originally scheduled, making it the same day as the latest CT scan was performed, so one of two reports was unavailable. That might impact the diagnosis.
UofU Patient
May 06, 2015
I have asked a friend in Austin Tx to seek treatment at Huntsman's
UofU Patient
May 01, 2015
we are on the right track with my cancer.
UofU Patient
April 06, 2015
I have the highest confidence in Dr. Agarwal. I feel his commitment to me as a patient has greatly enhanced my quality of life.
UofU Patient
March 19, 2015
We absolutely love Dr. Agarwahl!
UofU Patient
March 10, 2015
good
UofU Patient
February 24, 2015
I had only GOOD experiences!
UofU Patient
February 20, 2015
Dr. Agarwal and his staff are incredible. We have been together one year now and I consider them family. I look forward to seeing everyone: Dr. Agarwal the PA and study coordinator. Despite my personal challenges, they put me at ease and are always encouraging and positive. They are all blessings to me and my family. They have made a difference in my life. I love them all.
UofU Patient
February 17, 2015
Provided great additional information.
UofU Patient
February 17, 2015
I recmmend all of the time
UofU Patient
February 16, 2015
I already conveyed my concerns to patient advocate.
UofU Patient
February 07, 2015
Dr. Neeraj Agarwal spent probably 15 minutes discussing my psa and my future. This was a very good experience.
UofU Patient
January 25, 2015
very good
UofU Patient
January 17, 2015
Alternatives for future care were dumped before me. No evaluation of each, no Dr. recommendations, no assessment that was promised during previous visit were given. Copy of labs, bone scan and CAT scan were handed to me with "very little change" comment. No details were discussed. I was very disappointed with the visit. It seemed a waste of time and insurance dollars. My needs were not considered nor met.
UofU Patient
December 25, 2014
there is no comparison to the care that is recieved at Huntsman.
UofU Patient
December 21, 2014
I know the Nurse Practioner and Doctor were very busy, but they seemed very rushed. I felt that I didn't have enought time to ask the questions in which I needed answers. They answered questions but were very rushed. It wasn't like it was in previous visits.
UofU Patient
December 18, 2014
Doctor Agarwal and his staff have been friendly and courteous from the beginning. Our discussions have been enlightening comforting and at the same time factual. I can say without equivocation I have always felt that Doctor Agarwal and his staff have had my interests at heart
UofU Patient
December 17, 2014
My care provider is indeed concerned about me
UofU Patient
December 10, 2014
good
UofU Patient
November 17, 2014
Awesome staff; caring and professional
UofU Patient
November 17, 2014
good
UofU Patient
November 16, 2014
Dr Agarwal and his staff are excellent.
UofU Patient
November 13, 2014
The Doctor spent over an hour with us as he animatedly shared his "Introduction to Oncology" lecture, tied directly to my current condition.
UofU Patient
November 08, 2014
Very happy with the care provided to me. I don't mind travelling from California to see the doctor here in SLC.
UofU Patient
November 02, 2014
Everyone is always treating me with the utmost care and compassion for my cancer. Treatments are always explained very well and all staff members are the best to work with.
UofU Patient
October 12, 2014
Very knowledgeable and thorough and polite.
UofU Patient
October 06, 2014
Dr Agarwal is excellent.
UofU Patient
September 13, 2014
Great
UofU Patient
September 09, 2014
When my husband (the patient) broke down and cried, the doctor gave him a hug and reassured him.
UofU Patient
September 09, 2014
very confident with the knowledge of my DR and staff
UofU Patient
September 04, 2014
Everything is great.
UofU Patient
August 13, 2014
HUNTSMAN CANCER INSTITUTE is world class!
UofU Patient
August 09, 2014
Dr Agarwal has been wonderful.
UofU Patient
July 25, 2014
Excellent service and Outstanding and Congenial staff as always. I receive the very best care every time I am there. Thank you.
UofU Patient
July 15, 2014
Outstanding
UofU Patient
July 10, 2014
I have a lot of confidence in Doctor Agarwal.
UofU Patient
June 27, 2014
My cancer is stable. IVC and chemo and MindBody has got it stopped.
UofU Patient
June 07, 2014
My cancer is diminishing.
UofU Patient
May 16, 2014
All good Doc.
UofU Patient
May 15, 2014
There was a bit of confusion regarding the reasons for the ordered test due to multiple areas being addressed but this was cleared up with the next providers doing the tests.
UofU Patient
May 14, 2014
Great staff.
UofU Patient
May 10, 2014
Couldn't ask for better
UofU Patient
May 10, 2014
Dr. Agarwal is a very knowledgeable, caring professional. I am very fortunate to have him over my care.
UofU Patient
April 26, 2014
Everytime I visit with Dr. Agarwal, I realize that he is always determining what the next steps are in my treatment program. He is very informative and concerned with my progress. He is sensitive towards my needs as a patient and builds my confidence. His vast knowledge of the disease and forward thinking puts your mind at ease. I always highly recommend Dr. Agarwal to others.
UofU Patient
April 25, 2014
good
UofU Patient
April 14, 2014
Dr. Argawal provided me real answers to my problem and I am very happy to now have him as my doctor. He provided very good explanations and took the time to answer my questions.
UofU Patient
April 13, 2014
Some tech terms but I think I understand
UofU Patient
April 11, 2014
The care providers cound have not been more attnetative to our needs and questions. Everything was explained to us and our input was taken into consideration.
UofU Patient
April 03, 2014
still looking for who my care provider is. as far as I am concerned every one at HCI is my care provider.
UofU Patient
April 02, 2014
Good
UofU Patient
March 30, 2014
Staff know what they are doing and make things easier for family to understand more about my illness.
UofU Patient
March 02, 2014
The staff and doctors were excellent!
UofU Patient
February 22, 2014
Seems like I spend a lot of time at Huntsman. Everyone is always very nice and courteous! I have never had a bad experience! The Valet service is a huge plus especially when you might not be having the best of days! My hat off to everyone!
UofU Patient
February 12, 2014
Professional, congenial, and clearly caring in every way. I was pampered and treated like a friend or family member. I am convinced my welfare and wellbeing really matters to the folks at HCC
UofU Patient
February 12, 2014
Dr. Agarwal spent a lot of time outlining different treatment options, most of which were not really an option for me. He also mentioned more than once he had other patients he needed to see. He did ask form one of the Nurses in the IL-2 treatment to come talk with us. She added a lot to what he said. I was called on the following day to let me know about an appointment on that Monday they had scheduled for me in Radiology without having addressed that during my appointment.
UofU Patient
February 12, 2014
All good
UofU Patient
February 10, 2014
Could not have asked for better people.
UofU Patient
February 07, 2014
Instilled a positive attitude in a stressful situation.
UofU Patient
January 20, 2014
Outstanding
UofU Patient
January 18, 2014
Always perfect.
UofU Patient
January 17, 2014
A lot of variation between Dr, PA and Nurses
UofU Patient
January 13, 2014
Excellent
UofU Patient
January 09, 2014
Outstanding in each of these categories. I did not think the physician and his assistant would have the kind of time for patient I received from both. I felt uniquely special and cared for and about. Thank you to Dr. Agarwal and Julia.
UofU Patient
December 16, 2013
The PA went out of her way to help me understand, She made a graft on the computer to show me the answer a question I had.
UofU Patient
November 20, 2013
They are so good to explaining everything.
UofU Patient
October 28, 2013
We have already recommended Huntsmans to a coworker with a newly diagnosed cancer.
UofU Patient
October 02, 2013
good
UofU Patient
September 20, 2013
care provider made me feel I was the only patient he had.
UofU Patient
August 26, 2013
Every visit I've made to this clinic has always been a good experience.
UofU Patient
August 20, 2013
Dr Agarwal and the nurse practitioners have always been great. They clearly have out best interest at heart and seem invested in us and our progress towards a cure. This time we also saw Steve - pharmacist - he was just as kind as could be and very informative. It is just great how all the disciplines seem to be there, on the spot, when needed.
UofU Patient
August 19, 2013
Dr. Agerwal is the best!!! We love him
UofU Patient
August 08, 2013
Dr. Agerwal is always concerned, kind and willing to answer all questions to our satisfaction.
UofU Patient
July 22, 2013
I am very confident in Dr. Agarwall. He always takes the time to make sure I understand what is going on even though I have been doing whole brain radiation and get confused often.
UofU Patient
July 08, 2013
Again, very impressed and grateful to all.
UofU Patient
June 02, 2013
Everyone was most concerned and helpful.
UofU Patient
May 29, 2013
Great experience
UofU Patient
April 22, 2013
I truly don't know what we would ever do with our Doctor! He is amazing and kind and we know that he truly cares and wants the very best for my husband. He is an amazing man!!!
UofU Patient
April 01, 2013
Every experience I have had at Huntsman has been great. I look forward to driving down from Idaho to not only be treated but vcisit with Doctors and staff. Don't chgange anything.
UofU Patient
March 12, 2013
The visit was very helpful. I felt quite confident about the info.
UofU Patient
March 04, 2013
Dr Agarwal went out of his way to make sure that we understood the risk/reward of the IL 2 therapy, included us in the decision making process, and also welcomed a friend who was sitting on on the session. We left feeling completely confident in the care we would receive from Dr Agarwal and the Nurse practitioners who administer the treatment.
UofU Patient
March 04, 2013
I always feel that everyone is proactively involved in my case and has a personal interest in my progress. I know I am in good hands at the Huntsman.
UofU Patient
February 25, 2013
Narraj is great and is so caring.
UofU Patient
February 25, 2013
As usual. Unbelievable care.
UofU Patient
February 18, 2013
I have recommended and I will continue to recommended my care provider Dr Neeraj Agarwal and his staff to others. I appreciate their committed positive approach to my treatment.
UofU Patient
February 10, 2013
I frequently mention to others about the good experience I have had at HCC. The level of treatment and experience of the doctors is exceptional. The treatment and the facility are world class! Thank you
UofU Patient
January 28, 2013
This visit is the best one I have experienced so far. Keep up the good work.
UofU Patient
January 14, 2013
Pleasantly surprised at the knowledge the provider had of my case upon arrival without looking at notes and the unrushed atmosphere and amount of time spent with me.
UofU Patient
November 27, 2012
We told them about my "flu like" symptoms after my first infusion and they immediately recommended changes in the procedure that would help me to avoid those "flu like" symptoms in the future
UofU Patient
November 12, 2012
The entire Staff at HCI is on the cutting edge in their profession. I have the highest confidence in their direction and treatment.
UofU Patient
November 12, 2012
Every one is great!!!!!!!!!!
UofU Patient
October 29, 2012
If you have Cancer, This is the place to come to for treatment.
UofU Patient
October 22, 2012
Dr. Agarawal was very clear, professional and straightforward in his manner.
UofU Patient
October 12, 2012
I can understand how a Doctor's schedule can be disrupted. I do not understand why I was not better informed of reason for the delay. I certainly do not know why I waited in the Infusion Clinic for nearly 90 minutes because, as I understand, Pharmacy was slow.
UofU Patient
July 30, 2012
I personaly do not like the doctor
UofU Patient
July 16, 2012
We tell everyone this is the best place for excelant care.
UofU Patient
June 26, 2012
Dr. Agarwal is apparently very knowledgeable and proficient medically, but I have found his patient concern and communication skills to be lacking. He demonstrates superficial concern and does a very marginal job of explaining his treatments and taking time to insure that the patient has a comfortable understanding of treatment/changes in treatments. He gives the distinct impression that his "schedule" and clinical studies are much more important that your concerns/comfort level.
UofU Patient
June 25, 2012
they were busy that day but I had no problem
UofU Patient
May 04, 2012
GOOD
UofU Patient
April 13, 2012
thanks for the great care I have been afford in helping me fight my cancer.
UofU Patient
March 23, 2012
Dr. who spoke to us and examined me before Dr. Agarwal was very knowledgeable, and during exam found a potential concern which he told him about.
UofU Patient
March 16, 2012
good
UofU Patient
February 29, 2012
In the three years I have been at the Huntsman Center I can say it has been a pleasant experience and I would highly recommend it to everyone
UofU Patient
February 08, 2012
Good experience
UofU Patient
January 27, 2012
I was well taken care of. I didn't know what to expect. I trust these people to do their best for me.
UofU Patient
January 10, 2012
Very good.
Dr. Neeraj Agarwal, MD, a Profesor of medicine, is a physician and an investigator at the Huntsman Cancer Institute (HCI), University of Utah. At the HCI, he directs the Genitourinary Oncology (GU) Program, the Center of Investigational Therapeutics (CIT), co-leads the Experimental Therapeutic Program (one of the four cancer center support grant programs at the HCI), and serves on the cabinet of the Director of HCI.
Dr. Agarwal has authored more than 200 peer-reviewed articles and book chapters. He has been invited to give talks at several national and international forums, including the National Institute of Health, and the annual meetings of American Society of Clinical Oncology (ASCO), Society of Urology Oncology (SUO), and Kidney Cancer Association (KCA), Brazilian Society of Urology, Spanish Genitourinary Oncology Group (SOGUG), and various National Cancer Institute (NCI) designated comprehensive cancer centers across the country. He serves as a panel member for the NCCN guideline- committees for bladder, and kidney cancer, and as a consultant to the oncology drug advisory committee (ODAC) to the United States Food and Drug Administration (FDA).
Dr. Agarwal is the overall study chair of multiple clinical trials, including two phase III registration trials, multiple phase II and I trials, and eight investigator initiated clinical trials in GU cancers. In addition, he is leading several other clinical trials as one of the steering committee members. Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences (AIIMS) in New Delhi, India, Dr. Agarwal completed a residency in internal medicine, and a fellowship in geriatric medicine, at the University of Iowa. He then completed a hematology-oncology fellowship at the Huntsman Cancer Institute at the University of Utah.
Dr. Agarwal has the prestigious honor of being chosen as one of the five SWOG young investigators in 2009, as the leader of early therapeutics of the SWOG Genitourinary Cancer Scientific leadership Committee in 2010, of receiving the 2009-2010 William D. Odell Young Investigator award, and the 2014 Cancer Clinical Investigator Team Leadership Award from the NCI. In 2018, he was appointed as Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research.
Academic Locations
Huntsman Cancer Institute
801-213-5658
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Cancer Center Programs | Experimental Therapeutics |
Education History
| Fellowship | University of Utah School of Medicine Hematology/Oncology Fellow |
| Fellowship | University of Iowa Hospitals and Clinics Geriatrics Fellow |
| Residency | University of Iowa Hospitals and Clinics Internal Medicine Resident |
| Internship | Advocate Illinois Masonic Medical Center Internal Medicine Intern |
| Professional Medical | All India Institute of Medical Sciences Medicine M.D. |
| Professional Medical | Assam Medical College Medicine M.B.B.S. |
Selected Publications - Journal Articles
Journal Article
- Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK (2020). Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. (Epub ahead of print) JAMA Oncol.
- McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK (2020). Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. (Epub ahead of print) Invest New Drugs.
- de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. (Epub ahead of print) N Engl J Med.
- Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN (2020). Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 38(10), 1081.
- Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. (Epub ahead of print) Clin Genitourin Cancer.
- Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(3), 329-354.
- Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM Jr, Quinn DI, Yu EY (2020). Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. (Epub ahead of print) Prostate Cancer Prostatic Dis.
- Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucian R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A (2020). Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. (Epub ahead of print) Clin Genitourin Cancer.
- Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M (2020). Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. (Epub ahead of print) Clin Cancer Res.
- Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P (2020). Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol, 101097JU0000000000000761.
- Hahn AW, Sirohi D, Agarwal N (2019). The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. Eur Urol Focus, 6(1), 11-13.
- Agarwal N, Nussenzveig RH, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks JL, Santos VS, Nachaegari G, Wang X, Boucher KM, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. (Epub ahead of print) Clin Cancer Res.
- Johnson E, Nussenzveig R, Agarwal N, Swami U (2019). Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 21(1), 75-81.
- Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol, 4, 370-381.
- Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H (2019). Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol, JCO1902768.
- Swami U, Yap JT, Agarwal N (2019). Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. (Epub ahead of print) JAMA Oncol.
- Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comprat E, Crabb S, Culine S, Bari B, Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espins E, Lgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Mller AC, Mller CR, NDow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprt M, Rouvire O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskime E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA (2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (Epub ahead of print) Ann Oncol.
- Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O (2019). Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. (Epub ahead of print) Oncologist.
- Pal S, Hu-Lieskovan S, Agarwal N (2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? Lancet Oncol, 20(11), 1473-1474.
- Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, zgrolu M, Jurez Soto, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol, 20(11), 1518-1530.
- Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD (2019). First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol, 2(6), 708-715.
- Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G (2019). NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw, 17(11), 1278-1285.
- Hahn AW, Pal SK, Agarwal N (2019). Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. (Epub ahead of print) Oncologist.
- Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Thodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A, RISC Investigators (2019). Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Eur Urol, 76(4), 425-429.
- Nandagopal L, Sonpavde GP, Agarwal N (2019). Investigational MET inhibitors to treat Renal cell carcinoma. Expert Opin Investig Drugs, 28(10), 851-860.
- Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD (2019). The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 24(10), 1348-1355.
- Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (Epub ahead of print) Oncologist.
- Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR (2019). A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist, 24(9), 1151-e817.
- Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A, RISC Investigators (2019). Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. (Epub ahead of print) Eur Urol Oncol.
- Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Jurez Soto, Merseburger AS, zgrolu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med, 381(1), 13-24.
- Swami U, Pal SK, Agarwal N (2019). Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. (Epub ahead of print) JAMA Oncol.
- Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol, 37(6), 352.e19-352.e24.
- Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Thodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A (2018). Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Eur Urol Oncol, 2(3), 248-256.
- Corn PG, Agarwal N, Araujo JC, Sonpavde G (2017). Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus, 5(3), 369-380.
- Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 37(13), 1051-1061.
- Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL (2019). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. 36(5), 395-401.
- Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB (2019). Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer, 125(9), 1459-1469.
- Swami U, Grivas P, Agarwal N (2019). The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. Oncologist, 24(5), 580-583.
- Martnez Chanz N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol, 20(4), 581-590.
- Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE (2019). Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol, 37(10), 834-849.
- Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF (2019). Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer, 7(1), 84.
- Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP (2019). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. (Epub ahead of print) Eur Urol Oncol.
- Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium group (2019). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus, 5(2), 242-249.
- Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N (2019). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther, 18(3), 726-729.
- Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW (2019). Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol, 20(2), 14.
- Hahn AW, Pal SK, Agarwal N (2019). Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist, 24(2), 143-145.
- Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Sthler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY (2019). Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clin Genitourin Cancer, 17(1), 65-71.
- Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC, RISC Investigators (2019). Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. (Epub ahead of print) Eur Urol Oncol.
- Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE, 14(1), e0210415.
- Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N (2019). Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precis Oncol, 3.
- Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N (2019). Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol, 10(1), 149-154.
- Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N (2019). Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun, 19, 100120.
- Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N (2019). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun, 19, 100116.
- Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium RISC (2018). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus, 4(6), 937-945.
- Agarwal N, Nussenzveig R, Pal SK (2018). Biomarkers in renal-cell carcinoma: building on clinical paradigms. Lancet Oncol, 19(12), 1560-1561.
- Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151.
- Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, Agarwal N (2018). Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer, 16(5), 365-368.
- Hamieh L, Choueiri TK, Ogrek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ (2018). Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet, 14(9), e1007679.
- Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA (2018). NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(9), 1041-1053.
- Hahn AW, Gill DM, Nussenzveig RH, Poole A, Farnham J, Cannon-Albright L, Agarwal N (2018). Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 16(4), 288-292.
- Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B (2018). Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 124(15), 3105-3117.
- Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N (2018). Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. J Manag Care Spec Pharm, 24(6), 525-533.
- Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124.
- Dorff TB, Agarwal N (2018). Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian J Androl, 20(3), 215-220.
- Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 24(3), 190-197.
- Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2018). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382.
- Hahn AW, Pal SK, Agarwal N (2018). HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncol, 4(4), 562-563.
- Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD, Retrospective International Study of InvasiveAdvanced Cancer of the Urothelium Group (2018). Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer, 16(2), e483-e490.
- Stukalin I, Wells CJ, Fraccon A, Pasini F, Porta C, Lalani AA, Srinivas S, Bowman AI, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanesvaran R, Choueiri TK, Heng DYC (2018). Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer, 2(1), 31-36.
- Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B (2018). Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circ Heart Fail, 11(3), e004408.
- Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD (2018). Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol, 29(2), 361-369.
- Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM Jr, Tewari M, Yu EY (2018). Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate, 78(2), 121-127.
- Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH (2018). Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol, 73(1), 71-78.
- Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI (2017). Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer, 15(6), 635-641.
- Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr (2017). Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol, 3(11), e170231.
- Bergerot P, Agarwal N, Pal SK, Jones J (2017). Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree. Clin Cancer Res, 23(21), 6381-6383.
- Hahn AW, Hale P, Rathi N, Agarwal N (2017). Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol, 27(6), 559-565.
- Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N (2017). Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Adv Ther, 34(11), 2452-2465.
- Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE (2017). Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. Clin Genitourin Cancer, 15(5), 526-533.
- Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Fam Cancer, 16(4), 545-550.
- Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK (2017). Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol, 72(4), 557-564.
- Hahn AW, Nussenzveig RH, Pal SK, Agarwal N (2017). Blood- and tissue-based tumor genomics: a battle royale or match made in heaven? Ann Oncol, 28(10), 2333-2335.
- Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(10), 1240-1267.
- Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. (Epub ahead of print) Clin Genitourin Cancer.
- Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I (2017). Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 9(10), 797-804.
- Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY, RISC Investigators (2017). Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. (Epub ahead of print) Clin Genitourin Cancer.
- Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602.
- Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ (2017). Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clin Genitourin Cancer, 15(4), e573-e582.
- Maia MC, Yang ES, Agarwal N, Pal SK (2017). A step towards predicting checkpoint inhibitor response in kidney cancer. Lancet Oncol, 18(8), 982-983.
- Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan D, Ky B (2017). Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res, 23(14), 3601-3609.
- Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L (2017). Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncol, 3(6), 856-857.
- Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC (2017). Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol, 71(6), 970-978.
- De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK (2017). Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer, 15(3), 403-410.e2.
- Hansberry DR, Donovan AL, Prabhu AV, Agarwal N, Cox M, Flanders AE (2017). Enhancing the Radiologist-Patient Relationship through Improved Communication: A Quantitative Readability Analysis in Spine Radiology. AJNR Am J Neuroradiol, 38(6), 1252-1256.
- Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R (2017). Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(6), 804-834.
- Gill DM, Agarwal N, Vaishampayan U (2017). Evolving Treatment Paradigm in Metestatic Renal Cell Carcinoma. PMID: 28561652. Am Soc Clin Oncol Educ Book.
- Hahn AW, Gill DM, Pal SK, Agarwal N (2017). The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 9(8), 681-692.
- Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
- Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC (2017). Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Med, 6(5), 902-909.
- Gill DM, Sonpavde G, Pal SK, Agarwal N (2017). Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy, 9(6), 463-466.
- Parker SJ, Pond GR, Agarwal N, Alex A, Heilbrun ME, Sonpavde G (2017). Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 15(1), 53-59.
- Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators (2017). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol, 71(2), 281-289.
- Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY (2017). Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 71(2), 204-209.
- Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S (2017). Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer, 15(1), 31-41.e4.
- Gupta S, Gill D, Poole A, Agarwal N (2017). Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers (Basel), 9(2).
- Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology, 17(1), 1.
- Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA (2017). Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. Prostate, 77(1), 41-48.
- Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS (2017). Reply to M.A.N. Sendur et al and J. Michels. J Clin Oncol, 35(1), 123.
- Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (2017). Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med, 6(1), 186-194.
- Maughan BL, Bailey E, Gill DM, Agarwal N (2017). Incidence of Immune-Related Adverse Events with Program Death Receptor-1-and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Front Oncol, 7, 56.
- Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP (2016). Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother, 65(12), 1533-1544.
- Gill D, Hahn AW, Sonpavde G, Agarwal N (2016). Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother, 12(12), 2997-3004.
- Pal SK, Agarwal N, Dizman N, Sonpavde G (2016). Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. Lancet Oncol, 17(11), 1477-1478.
- Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
- Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DYC, Choueiri TK (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol, 34(30), 3655-3663.
- Agarwal N, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. J Urol, 196(4), 1112-6.
- Agarwal N, Shuch B, Pal SK (2016). Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma. JAMA Oncol, 2(10), 1273-1274.
- Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw, 14(10), 1213-1224.
- Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N (2016). Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. Am J Clin Oncol, 39(5), 497-506.
- Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
- Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER (2016). National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol, 34(27), 3346-8.
- Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bogemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 34(22), 2636-43.
- Pal SK, Agarwal N (2016). Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat Rev Urol, 13(8), 442-3.
- Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A (2016). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother, 65(8), 941-9.
- Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ (2016). Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer, 14(4), 331-40.
- Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ (2016). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol, 17(7), 917-927.
- Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016). Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol, 34(18), 2098-106.
- Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S (2016). Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res, 22(10), 2445-2452.
- Agarwal N, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M (2016). Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, 21(5), 535-6.
- Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
- Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
- Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
- Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
- Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO (2015). Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Mol Cancer Ther, 14(12), 2896-900.
- Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15, 15.
- Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE (2015). Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 121(15), 2586-93.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015). Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw, 13(6), 772-99.
- Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9.
- Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY (2015). Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis, 18(2), 122-7.
- Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
- Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr (2015). SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol, 33(14), 1601-8.
- Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI (2015). Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer, 136(8), 1856-62.
- Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY (2015). Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin Genitourin Cancer, 13(2), 150-5.
- Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO (2015). Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer, 13(2), 130-6.
- Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, 13(2), e79-85.
- Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G (2015). Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer, 13(2), 178-84.
- Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol, 16(3), 293-300.
- Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R (2015). Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol, 33(7), 723-31.
- Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LA (2015). Prostate cancer risk prediction based on complete prostate cancer family history. Prostate, 75(4), 390-8.
- Campo RA, Light KC, OConnor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas LM, Boucher KM, Irwin MR, Hill HR, Martins TB, Agarwal N, Kinney AY (2015). Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv, 9(1), 115-25.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R, National comprehensive cancer network (2015). Kidney cancer, version 3.2015. J Natl Compr Canc Netw, 13(2), 151-9.
- Singh P, Pal SK, Alex A, Agarwal N (2015). Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol, 11(15), 2137-48.
- Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
- Reese Z, Straubhar A, Pal SK, Agarwal N (2015). Ipilimumab in the treatment of prostate cancer. Future Oncol, 11(1), 27-37.
- Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 66(4), 704-10.
- Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T (2014). Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother, 37(7), 360-5.
- Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD (2014). Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist, 19(9), 915-6.
- Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD (2014). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol, 9(3), 195-204.
- Agarwal N, Dorff T, Goldkorn A (2014). New prostate cancer drugs: extending and improving life. Lancet Oncol, 15(10), 1052-4.
- Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC (2014). A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 120(17), 2684-93.
- Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 15(7), 700-12.
- Cannon-Albright LA, Farnham JM, Bailey M, Albright FS, Teerlink CC, Agarwal N, Stephenson RA, Thomas A (2014). Identification of specific Y chromosomes associated with increased prostate cancer risk. Prostate, 74(9), 991-8.
- Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY (2014). Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol, 65(6), 1086-92.
- Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, ODonnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G (2014). A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int, 113(5b), E137-43.
- Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer, 110(8), 1917-22.
- Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ (2014). Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol, 32(11), 1136-42.
- Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
- Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK (2014). The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol, 65(4), 723-30.
- Campo RA, Agarwal N, LaStayo PC, OConnor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney AY (2014). Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv, 8(1), 60-9.
- Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA (2014). Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol, 9(1), 63-71.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, Natiomal compresensive cancer networks (2014). Kidney cancer, version 2.2014. J Natl Compr Canc Netw, 12(2), 175-82.
- Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2014). Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev, 40(1), 190-6.
- Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9.
- Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol, 25(1), 149-54.
- Swierczek S, Agarwal AM, Naidoo K, Lorenzo FR, Whisenant J, Nussenzveig RH, Agarwal N, Coetzer TL, Prchal JT (2013). Novel exon 2 alpha spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct alpha spectrin defects. Haematologica, 98(12), 1972-9.
- Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, Aizad H, Hughen RW, Bateman L, Light AR (2013). Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology, 38(12), 2983-95.
- Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G (2013). Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer, 11(4), 495-500.
- Campo RA, OConnor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY (2013). Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integrative Cancer Therapies, 12(6), 464-74.
- Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
- Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY (2013). The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol, 8(3), 203-209.
- Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 119(16), 2999-3006.
- Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013). Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol, 14(9), 893-900.
- Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney AY (2013). Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res, 13, 279.
- Kunkalla K, Liu Y, Qu C, Leventaki V, Agarwal NK, Singh RR, Vega F (2013). Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol, 92(6), 777-87.
- Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network (2013). Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 594-615.
- Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, National Comprehensive Cancer Network NCCN (2013). Bladder cancer. J Natl Compr Canc Netw, 11(4), 446-75.
- Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol, 14(2), 141-8.
- Nelson Q, Agarwal N, Stephenson R, Cannon-Albright LA (2013). A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet, 4, 152.
- Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG (2012). A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw, 10(11), 1391-8.
- Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol, 13(9), 927-35.
- Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012). Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol, 30(12), 1371-7.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB, National Comprehensive Cancer Network (2012). Testicular cancer. J Natl Compr Canc Netw, 10(4), 502-35.
- Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9.
- Montejo ME, Shrieve DC, Bentz BG, Hunt JP, Buchman LO, Agarwal N, Hitchcock YJ (2011). IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 81(5), e845-52.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB, National Comprehensive Cancer Network (2011). Kidney cancer. J Natl Compr Canc Netw, 9(9), 960-77.
- Agarwal N, Sonpavde G, Sartor O (2011). Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol, 7(1), 15-24.
- Agarwal N, Batten J (2009). Optimal treatment in the postorchiectomy management of clinical stage I seminoma. Oncology (Williston Park), 23(9), 764, 767.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw, 7(6), 618-30.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw, 7(6), 672-93.
- Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. Review Series - Oncology, 12(2), 18-21.
- Agarwal N, Prchal JT (2009). Anemia of chronic disease (anemia of inflammation). Acta Haematol, 122(2-3), 103-8.
- Swierczek SI, Agarwal N, Nussenzveig RH, Rothstein G, Wilson A, Artz A, Prchal JT (2008). Hematopoiesis is not clonal in healthy elderly women. Blood, 112(8), 3186-93.
- Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, Agarwal N, Anderson S (2008). Community physicians' strategies for patients with medically unexplained symptoms. Fam Med, 40(2), 111-8.
- Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading NS, Bailey L, Kutlar A, Prchal JT (2007). Missense mutation of the last nucleotide of exon 1 (G->C) of beta globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. Haematologica, 92(12), 1715-6.
- Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT (2007). Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci, 4(4), 232-6.
- Nordin TA, Hartz AJ, Noyes R Jr, Anderson MC, Rosenbaum ME, James PA, Ely JW, Agarwal N, Levy BT (2006). Empirically identified goals for the management of unexplained symptoms. Fam Med, 38(7), 476-82.
- Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P (2001). A study of autoimmune markers in hepatitis C infection. Indian J Med Res, 113, 170-4.
Review
- Hahn AW, Gill DM, Agarwal N, Maughan BL (2017). PD-1 checkpoint inhibition: Toxicities and management. [Review]. Urol Oncol, 35(12), 701-707.
- Gill DM, Agarwal N (2017). Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. [Review]. Urol Oncol, 35(12), 676-677.
- Alex AB, Pal SK, Agarwal N (2016). CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. [Review]. Ther Adv Med Oncol, 8(4), 267-75.
- Gupta S, Gill D, Pal SK, Agarwal N (2015). Activin receptor inhibitors--dalantercept. [Review]. Curr Oncol Rep, 17(4), 14.
- Singh P, Agarwal N, Pal SK (2015). Sequencing systemic therapies for metastatic kidney cancer. [Review]. Curr Treat Options Oncol, 16(1), 316.
- Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014). New agents for prostate cancer. [Review]. Ann Oncol, 25(9), 1700-9.
- Agarwal N, Hussain M (2013). Management of hormone-sensitive metastatic prostate cancer. [Review]. Hematol Oncol Clin North Am, 27(6), 1221-41, viii.
- Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ (2013). Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. [Review]. Curr Urol Rep, 14(3), 174-83.
- Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. [Review]. Prostate Cancer, 2013, 981684.
- Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. [Review]. UroToday, UroToday.
- Agarwal N, Padmanabh S, Vogelzang NJ (2012). Development of novel immune interventions for prostate cancer. [Review]. Clin Genitourin Cancer, 10(2), 84-92.
- Agarwal N, Sonpavde G, Sternberg CN (2012). Novel molecular targets for the therapy of castration-resistant prostate cancer. [Review]. Eur Urol, 61(5), 950-60.
- Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. [Review]. Oncol Hematol Rev, 8(1): 30-8.
- Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW (2011). Recent advances in immunotherapy for the treatment of prostate cancer. [Review]. Expert Opin Biol Ther, 11(8), 997-1009.
- Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G (2010). Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. [Review]. Future Oncol, 6(5), 665-79.
- Agarwal N, Hussain M (2009). Management of bladder cancer: current and emerging strategies. [Review]. Drugs, 69(9), 1173-87.
- Agarwal N, Prchal JT (2008). Erythropoietic agents and the elderly. [Review]. Semin Hematol, 45(4), 267-75.
- Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? [Review]. Am J Hematol, 82(4), 295-8.
- Agarwal N, Spahr JE, Rodgers GM (2007). Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. [Review]. Blood Coagul Fibrinolysis, 18(2), 205-7.
- Agarwal N, Gordeuk RV, Prchal JT (2007). Genetic mechanisms underlying regulation of hemoglobin mass. [Review]. Adv Exp Med Biol, 618, 195-210.
Book Chapter
- Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments. In Katrina Mountfort (Ed.), Oncology & Hematology Review (12, pp. 82-8).
- Singh P, Albertson D, Pal SK, Agarwal N (2016). Mucinous, Signet Ring, Ductal, and Sarcomatoid Variants of Prostate Cancer. In Lance Pagliaro (Ed.), Rare Genitourinary Tumors (First Edition). New York: Springer.
- Poole A, Alva A, Batten JA, Agarwal N (2014). Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors. In Dicker AP, Trabulsi EJ, Kelly W (Eds.), Multidisciplinary Approach to Prostate Cancer. New York: Demos Medical Publishing.
- Agarwal N, Fishman M (2014). Immunologic Therapy of Renal Cell Carcinoma. In Oncology & Hematology Review (10, pp. 54-60).
- Kollepara SS, Tantravahi SK, Batten J, Agarwal N (2013). Integrating Emerging Science into Clinical Practice:Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer”. In Lopaczynski W, Srivastava R, and Maksymowicz W. (Eds.), Lost in Translation: Barriers in Incentives for Translational Research. Singapore: World Scientific Publishing Co Pte. Ltd.
- Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. In UroToday. UroToday.com.
- Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. In Oncology & Hematology Review (8, pp. 30-8).
- Agarwal N, Vogelzang NJ (2011). Development of novel immune interventions for genitor-urinary cancers. In Adrian Bot, Mihail Obrocea & Francesco Marincola (Eds.), Cancer Vaccines (1st Edition). London, UK: Informa Healthcare.
- Agarwal N, Rodgers GM (2009). Miscellaneous Causes of Thrombocytopenia. In Greer JP, Foerster J, Rodgers GM et al. (Eds.), Wintrobe's Clinical Hematology (Edition 12, 2, pp. 1326-1334). Lippincott Williams & Wilkins.
- Agarwal N, Gordeuk VR, Prchal JT (2009). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation (2007, pp. 195-210). New York: Springer.
- Agarwal N, Prchal JT (2009). Dyshemoglobinemia. In Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds.), Disorders of Hemoglobin, Genetics, Pathophysiology, and Clinical Management (2nd ed, pp. 607-622). New York: Cambridge University Press.
- Agarwal N, Prchal JT (2009). Methemoglobinemia and Other Dyshemoglobinemias. In Kaushansky K, Lichtman M, Beutler E, et al. (Eds.), Williams Hematology (8th edition). New York: McGraw-Hill.
- Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. In Review Series Oncology (12, pp. 18-21).
- Agarwal N, Gordeuk VR, Prchal JT (2007). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation. New York: Springer.
Case Report
- McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer.
- Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW (2018). DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). 9(4), 119-122.
- Merriman J, Tward J, Albertson D, Dechet C, Agarwal N (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. J Immunother, 39(2), 101-3.
- Sangle NA, Mao R, Shetty S, Schiffman JD, Dechet C, Layfield L, Agarwal N, Liu T (2013). Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol, 56(4), 428-33.
- Narayanan S, Callis-Duffin K, Batten J, Agarwal N (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci, 339(6), 580-1.
- Lim HY, Agarwal AM, Agarwal N, Ward JH (2009). Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J, 50(5), e178-80.
- Agarwal AM, Agarwal N, Glenn MJ, Lim MS (2007). Blastic transformation of low-grade follicular lymphoma. J Clin Oncol, 25(16), 2326-8.
- Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5.
- Agarwal N, Cherascu B (2002). Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine. J Postgrad Med, 48(3), 197-8.
- Sharma S, Dey AB, Agarwal N, Nagarkar KM, Gujral S (1999). Tuberculosis: a rare cause of splenic abscess. J Assoc Physicians India, 47(7), 740-1.
Editorial
- Barata P, Swami U, Agarwal N (2020). The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Rev Anticancer Ther, 20(3), 147-150.
- Pal SK, Swami U, Agarwal N (2019). Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. Eur Urol, 77(1), 22-23.
- Tripathi A, Lin E, Agarwal N (2019). Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. Ann Transl Med, 7(Suppl 6), S203.
- Maia MC, Grivas P, Agarwal N, Pal SK (2018). Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. Eur Urol, 73(4), 541-542.
- Pal SK, Maia MC, Dizman N, Agarwal N (2017). Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma? Eur Urol, 72(6), 972-973.
- Shuch B, Hahn AW, Agarwal N (2017). Current Treatment Landscape of Advanced Papillary Renal Cancer. J Clin Oncol, 35(26), 2981-2983.
- Pal SK, Karam JA, Bergerot P, Agarwal N (2016). Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma. J Clin Oncol, 34(32), 3825-3826.
- Agarwal N, Sonpavde G, Choueiri TK, Pal SK (2016). Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. Eur Urol, 70(1), 42-44.
- Pal SK, Agarwal N, Grivas P, Choueiri T (2016). Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. J Clin Oncol, 34(8), 777-9.
- Pal SK, Agarwal N, Jones JO (2015). Circulating tumor cells in prostate cancer: Does (nuclear) size matter? Cancer, 121(18), 3190-2.
- Agarwal N (2011). Editorial comment. J Urol, 186(3), 887; author reply 888.
- Agarwal N, Vogelzang NJ (2011). Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. BJU Int, 108(2), 227-8.
Letter
- Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol.
- Agarwal N, Lanman RB, Pal SK (2018). Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. [Letter to the editor]. JAMA Oncol, 4(10), 1429-1430.
- Agarwal N (2010). Hormonal therapy for prostate cancer in men with heart disease. [Letter to the editor]. JAMA, 303(1), 32-3; author reply 33.
- Agarwal N, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal JT (2009). Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? [Letter to the editor]. Blood, 114(11), 2357-8; author reply 2358-9.
- Chen A, Agarwal N (2009). Reversible posterior leucoencephalopathy syndrome associated with sunitinib. [Letter to the editor]. Internal Medicine Journal Online, 39(5), 341-2.
- Wada DA, Agarwal N, Florell SR, Lim MS (2008). Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma. [Letter to the editor]. Pathology, 40(3), 316-20.
- Yoon D, Agarwal N, Prchal JT (2008). Does erythropoietin promote tumor growth? [Letter to the editor]. Clin Cancer Res, 14(6), 1920; author reply 1920-1.
- Agarwal N, Fletcher D, Ward J (2007). Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot? [Letter to the editor]. Clin Cancer Res, 13(13), 4027.
- Agarwal N, Gordeuk VR, Prchal JT (2007). Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed. [Letter to the editor]. J Clin Oncol, 25(13), 1813-4; author reply 1815.
- Agarwal N, Tepe EM, Mishra A, Ward JH (2006). Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip. [Letter to the editor]. Ann Hematol, 85(10), 741-2.
- Agarwal N, Klix MM, Burns CP (2004). Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. [Letter to the editor]. Ann Intern Med, 141(1), 83-4.
Abstract
- Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, Giorgi UD, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G (2019). Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival (suppl; abstr e16017) [Abstract]. 37.
- Bandini M, Pederzoli Filippo, Madison R, Briganti A, Plimack ER, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Ali SM, Chung J, Necchi A (2019). Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets (suppl; abstr 4535) [Abstract]. 37.
- Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, Ryan CW, Pins M, Kolesar J, Vaena DA, Parikh RA, Hashmi M, Dutcher JP, DiPaola RS, Haas NB, Carducci MA (2019). Randomized, double-blind phase III study of pazopanib versus placebo in patients with mtastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810) (suppl; abstr 4502). [Abstract]. 37.
- Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPS, Given RW, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy SA, Chowdhury S (2019). First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) (suppl; abstr 5006) [Abstract]. 37.
- Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor O, Yandell M, Agarwal N (2019). Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients (suppl; abstr 5032) [Abstract]. 37.
- Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Hernandez C, Siemon-Hryczyk P, Goswami T, Loriot Y (2019). TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy (suppl; abstr TPS3153) [Abstract]. 37.
- Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Quek RGW, Czibere AG, Fizazi K (2019). TALAPRO-2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl; abstr TPS5092) [Abstract]. 37.
- Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Czibere AG, Fizazi K (2019). Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl; abstr 5076) [Abstract]. 37.
- Lin E, Nussenzveig R, Hahn AW, Yandell M, Harshman LC, Agarwal N, Tripathi A (2019). Immune correlates of CD73 expression in patients with urothelial carcinoma (UC) (suppl; abstr 4548) [Abstract]. 37.
- Grivas P, Puligandla M, Cole S, Courtney KD, Dreicer R, Gartrell BA, Cetnar JP, Dallera M, Galsky MD, Jain RK, Maughan BL, Agarwal N, Koshkin VS, Hahn NM, Carducci MA (2019). PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC) (suppl; abstr TPS4594). [Abstract]. 37.
- Rathkopf DE, Saleh MN, Tsai FYC, Bilen MA, Rosen LS, Gottardis M, Infante JR, Adams BJ, Liu L, Theuer CP, Freddo JL, Agarwal N (2019). An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (suppl; abstr e16542) [Abstract]. 37.
- Tannir NM, Agarwal N, Pal SK, Formiga MN, Guo J, Tagliaferri MA, Hannah AL, Zhang JY, OKeeffe BA, Cho DC (2019). A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma(suppl; abstr TPS4595) [Abstract]. 37.
- Hahn AW, Lin E, Esther J, Anderson N, Rathi N, Yandell M, Maughan BL, Agarwal N (2019). Genomic landscape of metastatic hormone senstitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA) (suppl; abstr 5043) [Abstract]. 37.
- Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N (2019). An analysis from The Cancer Genome Atlas database (suppl; abstr e16591) [Abstract]. 37.
- Necchi A, Pal SK, Ross JS, Madison R, Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung J, Ali SM (2019). Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development (suppl; abstr 4581) [Abstract]. 37.
- Hahn AW, Haaland B, Rathi N, Dizman N, Maughan BL, Pal SK, Agarwal N (2019). Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 580) [Abstract]. Journal of Clinical Oncology, 37.
- Hahn AW, Drake CG, Denmeade SR, Zakharia Y, Maughan BL, Kennedy EP, Link CJ, Vahanian NN, Hammers HJ, Agarwal N (2019). Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 590) [Abstract]. Journal of Clinical Oncology, 37.
- Agarwal N, Pal SK, Lauer RC, Chatta GS, Goel S, Singh P, Sundararajan S, Heaton C, Peterson C, Benaim E, Tagawa ST (2019). Results of a phase II study to evaluate the safety and efficacy of RX-0201 in combination with everolimus in subjects with metastatic renal cell carcinoma (mRCC) (suppl 7S; abstr 646) [Abstract]. Journal of Clinical Oncology, 37.
- Pal SK, Vaishampayan UN, Castellano DE, Necchi A, Van Herpen CML, Ramsingh G, Loriot Y, Agarwal N (2019). Phase 1b (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC) (suppl 7S; abstr TPS683) [Abstract]. Journal of Clinical Oncology, 37.
- Tannir NM, Agarwal N, Dawson NA, Motzer RJ, Jacobs CM, Choueiri TK, Hrom JS, Geynisman DM, Davis NB, Figlin RA, OKeeffe MK, Parikh JR, Vaena DA, Liu PY, OKeeffe B, Tran X, Escudier B (2019). CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma (suppl 7S; abstr TPS682) [Abstract]. Journal of Clinical Oncology, 37.
- Ko L, Lilly MB, Hahn AW, Nussenzveig R, Moses MM, Ledet E, Manogue C, Cotogno P, Lewis BE, Layton JL, Agarwal N, Sartor AO, Barata PC (2019). Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate (suppl 7S; abstr 320) [Abstract]. Journal of Clinical Oncology, 37.
- Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Siemon-Hryczyk P, Goswam T, Loriot Y (2019). TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy (suppl 7S; abstr TPS495) [Abstract]. Journal of Clinical Oncology, 37.
- Griswold CR, Bailey EB, Mauser JC, Boucher KM, Agarwal N, Gupta S, Maughan BL (2019). Risk factors for venous thromboembolism (VTE) during chemotherapy in patients with germ cell tumors (GCT) (suppl 7S; abstr 520) [Abstract]. Journal of Clinical Oncology, 37.
- Pal SK, Szeto C, Reddy SK, Nussenzveig R, Lam RY, Scholz MC, Agarwal N (2019). Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prosate cancer (mCRPC) (suppl 7S; abstr 286) [Abstract]. Journal of Clinical Oncology, 37.
- Tward JD, ONeil B, Stephenson RA, Agarwal N, Farr T, Petragallo R, Lowrance WT (2019). Survival outcomes for adjuvant or salvage radiation in men with pN+M0 prostate cancer (suppl 7S; abstr 276) [Abstract]. Journal of Clinical Oncology, 37.
- Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Casey M, Quek RGW, Czibere A, Fizazi K (2019). TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) (suppl 7S; abstr TPS337) [Abstract]. Journal of Clinical Oncology, 37.
- Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor AO, Yandell M, Agarwal N (2019). Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) (suppl 7S; abstr 226) [Abstract]. Journal of Clinical Oncology, 37.
- Teerlink C, Hahn AW, Esther J, Rathi N, Farnham JM, Agarwal N, Cannon-Albright L (2019). Genome-wide association study of metastatic prostate cancer (suppl 7S; abstr 160) [Abstract]. Journal of Clinical Oncology, 37.
- Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD (2018). Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. PMID: 30292628 [Abstract]. Clinical Genitourinary Cancer.
- Tripathi A, Agarwal N (2018). Editorial Comment. PMID: 30189185 [Abstract]. The Journal of Urology.
- Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N (2018). Metastatic Castration-Sensitive Prosate Cancer: Optimizing Patient Selection and Treatment. PMID: 30231388 [Abstract]. American Society of Clinical Oncology (ASCO) Educational Book.
- De Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SK, Olmos D, Shore ND, Saad F, Liu S, Goessl CD, Burgents J (2017). PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration [Abstract]. Journal of Clinical Oncology.
- Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN, Larkin JMG, Rosbrook B, Lechuga M, Valota O, Tarazi JC, Shepard DR (2017). Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results [Abstract]. Journal of Clinical Oncology.
- Bergerot PG, Sonpavde G, Nelson RA, Agarwal N, Costa CN, Hsu J, Choueiri TK, Pal SK (2016). Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4540).
- Goldkorn A, Plets M, Agarwal N, Hussain M, Lara P, Vaena DA, MacVicar GR, Crispino T, Harzstark AL, Twardowski P, Tangen CM, Hugen CM, Xu T, Xu Y, Pinski JK, Ingles SA, Higano CS, Vogelzang NJ, Thompson IM, Quinn DI (2016). Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 11516).
- Agarwal N, Tagawa ST, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E (2016). Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 2559).
- Wells JC, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Knox JJ, Beuselinck B, Rha SY, Agarwal N, Brugarolas J, Lee JL, Pal SK, Srinivas S, Ernst DS, Vaishampayan UN, Wood L, Simpson R, Velasco G, Choueiri TK, Heng DYC (2016). Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4554).
- Sonpavde G, Nelson RA, Trinh Q, Agarwal N, Nix J, Kardos S, Bellmunt J, Choueiri TK, Pal SK (2016). Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4524).
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5083).
- Pond GR, Sonpavde G, Plets M, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI (2016). Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5079).
- Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB (2016). Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5035).
- Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz A, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4528).
- Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5066).
- Davis ID, Xie W, Pezaro CJ, Donskov F, Wells C, Agarwal N, Srinivas Sandhya, Yuasa T, Beuselinck B, Wood L, Ernst DS, Kanesvaran R, Knox JJ, Pantuck AJ, Saleem S, Alva AS, Rini BI, Lee JL, Choueiri TK, Heng DYC (2016). Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 534).
- Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood L, Kollmannsberger CK, Rha SY, North SA, Kanesvaran R, Rini BI, Broom RJ, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK (2016). DiscontinuingVEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 503).
- Ramos, J, Wong YN, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR, Powles T, Rosenberg JE, Giorgi UD, Vaishampayan UN, Agarwal N, Pal SK, Harshman LC, Necchi A, Recine F, Galsky MD, Yu EY, RISC Investigators (2016). Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 422).
- Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK (2016). Subgroup analysis of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 499).
- Li H, Kroeger N, deVelasco G, Donskov F, Sim HW, Wells C, Stukalin I, Agarwal N, Parekh HD, Rini BI, Knox JJ, Pantuck AJ, Choueiri TK, Heng DYC (2016). The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 552).
- Buckley TH, Alex A, Farnham JM, Gill D, Patel SB, Teerlink C, Albright FS, Stephenson, RA, Cannon-Albright LA, Agarwal N (2016). Assiciation of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 222).
- Gill D, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 224).
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill D, Patel SB, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 269).
- Sonpavde G, Nagy RJ, Apolo AB, Agarwal N, Pal SK, Grivas P, Vaishampayan UN, Lanman RB, Talasaz A (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 358).
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 610).
- Bergerot PG, Nelson RA, Ye DW, Grivas P, Singh P, Agarwal N, Choueiri TK, Pal SK (2016). Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic magnancies. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 363).
- Parker SJ, Pond GR, Sonpavde G, Alex A, Heilbrun ME, Agarwal N (2016). Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 191).
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 608).
- Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Grossmann KF, Samlowski WE, Redman BG, Agarwal N, Alva AS (2015). Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015(suppl; abstr 4565).
- Twardowski P, Plets M, Plimack ER, Agarwal N, Tangen CM, Vogelzang NJ, Thompson IM, Lara P (2015). SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4523).
- Harshman LC, Werner L, Wong Y, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Recine F, Bellmunt J, Galsky MD, RISC Investigators (2015). Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4524).
- Palmbos PL, Feng FY, Tomlins SA, Kelly WK, Morgans AK, Taplin M, Agarwal N, Antonarakis ES, Twardowski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M (2015). A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr TPS5074).
- Li H, Choueiri TK, Welss C, Agarwal N, Donskov F, Lee J, Broom RJ, Yuasa T, Rini BI, Pal SK, Wood L, Ernst DS, Kollmannsberger CK, Vaishampayan UN, Rha SY, Bjarnason GA, Knox JJ, Saleem S, Beuselinck B, Heng DYC (2015). Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4558).
- Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8 and reponse to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 5048).
- Fay AP, Kwiatkowski DJ, Gray KP, Thorner A, Rini BI, Agarwal N, Ho TH, Song J, Barrios PM, Albiges L, Mendel Van Allen E, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DYC, Signoretti S, Choueiri TK (2015). Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4519).
- Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N (May 2015). Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
- Flaig TW, Tangen CM, Hussain M, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM (February 2015). Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Eigl BJ (February 2015). Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Sternberg CN, Alva AS, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (February 2015). Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (February 2015). Germ line predictors of response to androgen deprivation therapy in men with advanced prostate cancer. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (February 2015). Correlation of baseline serum testosterone (T) and prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients (pts) with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continous androgen deprivation therapy (cADT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Tanravahi SK, Patel SB, Ravulapati S, Batten JA, Merriman J, Stenehjem D, Agarwal N (February 2015). Long-term response in metastatic renal cell carcinoma patients receiving first-line therapy with VEGF TKIs. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Alex A, Cannon-Albright LA (February 2015). Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Cannon-Albright LA, Teerlink C, Alex A, Albright FS, Stephenson RA, Agarwal N (February 2015). A genome-wide linkage study of lethal prostate cancer predisposition gene in a set of high-risk pedigrees. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (February 2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (February 2015). Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Stenehjem D, Parikh K, Batten J, Van Atta J, Crispin H, Sageser D, Grossmann K, Wang J, Tantravahi SK, Samlowski W, Agarwal N (2014). Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). [Abstract]. Journal Of Clinical Oncology.
- Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I (May 2014). SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
- Agarwal N, Parikh K, Tantravahi SK, Van Atta J, Batten J, Sageser D, Samlowski W, Grossmann K, Wang J, Stenehjem D (May 2014). Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract]. Journal of Clinical Oncology.
- Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
- Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I (May 2014). SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
- Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E (May 2014). Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted. [Abstract].
- Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J (May 2014). Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
- Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, Chin Heng DY, Choueiri T (May 2014). The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell cancer database consortium. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
- Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R (May 2014). Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
- Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (May 2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted. [Abstract].
- Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30–June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
- Tantravahi SK, Stenehjem DD, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang JF, Liu T, Agarwal N (January 2014). Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 535.
- Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Tantravahi SK, Agarwal N (January 2014). Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 460.
- Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N (January 2014). The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstra 487.
- Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonarakis ES, Yu EY (January 2015). The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
- Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD (January 2014). Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
- Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Kanesvaran R, Choueiri TK (January 2014). Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Jorunal of Clinical Oncology, 32(suppl 4), abstr 396.
- Ko JJ, Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK (January 2014). The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 398.
- Chittoria N, Zhu H, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox J, Bjarnason BA, MacKenzie MK, Wood L, Vaishamayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, North SA, Rini BI, Yick D, Heng C (2013). Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. Poster Presentation. May 31-Jun 4, 2013.ASCO annual meeting Washington D.C. [Abstract].
- Sonpavde G, Pond GR, Agarwal N, Choueiri TK, Qu AQ, Fougeray R, Salhi Y, Vaughn DJ, James ND, Niegisch G, Albers P, Galsky MD, Wong YN, Stadler WM, ODonnell PH, Vogelzang NH, Sridhar SS, Ko YJ, Sternberg CN, Bellmunt J (2013). Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013. [Abstract].
- Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S (2013). Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies. Accepted for Poster Presentation (Abstract: 1187): April, 8, 2013 AACR annual meeting. Washington, DC [Abstract].
- Munster P, van der Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (9/2012). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology.
- Kinney A, Birmingham W, Kohlmann W, Agarwal N (August 2012). Patients and providers cognitions regarding genomic risk assessments for prostate cancer susceptibility and cancer prevention. Oral Presentation Aug 2012 Prague, Czech Republic [Abstract]. European Health Psychology Society.
- Heng DYC, Xie WL, Choueiri TK, Lee J, Harshman LC, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, and Choueiri TK (2012). An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 353).
- Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, LorussoV, Moore MJ, Galsky MD, Sonpavde G (2012). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. (Abstract #308). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(Suppl 5), abstr 308.
- Heng DYC, Lee JL, Harshman LC, Bjarnason G, Razak AR, MacKenzie MJ, Wood L, Vaishampayan UI, Tan MH, Ran SY, Donskov F, Agarwal N, Kollmannsberger CK, North S, Rini BI, Choueiri TK, International mRCC Database Consortium (2012). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 387).
- Choueiri TK, Xie WL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Wood L, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Heng DYC (2012). Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) targeted therapy (TT): Results from the international mRCC database consortium. Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(suppl 5), abstr 358.
- Heng DYC, ChoueiriTK, Lee JL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North, S, A, Rini BI, Wood L (2012). A multicentered population based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. (Abstract 353). Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012.
- Kanth P, Stayner J, Grossman K, Agarwal N, Peterson K, Boynton K, Fang J, Valentine J, Bronner M, Burt R, Jewel Samadder N (2012). Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody (Ipilimumab) Associated Enterocolitis. Poster Presentation (P861)ACG), 77th Annual Meeting, October 19 - 24, 2012, Las Vegas, Nevada [Abstract]. American College of Gasteroenterology.
- Sharma S, Voest E, Hagner N, Witteveen PO, Lolkema M, Agarwal N, Valera S, Li J, Mires D, Porro MG, Woo MM, and Hess D (Nov 2011). Effects of Renal Function on the Pharmacokinetics of Panobinostate in Patients with Advanced Cancer: A Phase I Study. [Abstract]. Blood, 118, 5001.
- Hess D, Hagner N, Clive S, Gelderblom H, Rossmann E, Agarwal N, Grazia Porro M, Hengelage T, St-Pierre A, Gazi L, Li J, Woo MM, Sharma S (Nov 2011). Effects of Hepatic Funtion on the Pharmacokinetics and Safety of Panobinostate in Patients with Advanced Cancer: A Phase I Study. (ASH Annual Meeting Abstracts). [Abstract]. Blood, 118, 5007.
- Cannon Albright LA, Teerlink C, Agarwal N, Stephenson R (2011). Evidence for a strong genetic contribution to lethal prostate cancer (Abstract-1205W). Poster Presentation International Congress of Human Genetics/ American Society of Human Genetics. October 11-15, 2011, Montreal, Quebec, Canada [Abstract].
- Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UL, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan MH, Rha SY, Donskov F, North S, Choueiri TK, Heng DYC (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011 [Abstract]. J Clin Oncol 29:2011 (suppl; abstr 5563.
- Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas R, Sharma S (2011). A drug-drug interaction study of everolimus (a mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [suppl; abstr e15077] [Abstract]. J Clin Oncol, 29(suppl), e15077.
- Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T (2011). Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. [Abstract]. J Clin Oncol, 29(suppl), e15079.
- Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng KK, Xiao H, Haque S, Pfister DG (05/23/2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June, 2011 [Abstract]. J Clin Oncol, 29(Suppl), abstr 5563.
- Grossmann KF, Blankenship MB, Akerley W, Terrazas MC, Kosak KM, Boucher KM, Buys SS, Jones K, Werner TL, Agarwal N, Weis J, Sharma S, Ward JH, Shami PJ (2011). A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Abstract 1308 AACR. 2011 Apr 2-6; Orlando, Florida (FL): 2011. [Abstract].
- Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M (2010). Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 4-8, 2010. [J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239)] [Abstract]. J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239).
- Agarwal N, Swierczek S, Nussenzveig RH, Samuelson S, Parker CJ, Prchal JT (2008). Validation of a novel clonality assay in patients with clonal hematologic disorders. [Abstract]. Blood 2008; 112: Abstract 3718.
- Agarwal, N, Swierczek S, Rothstein G, Nussenzveig R, Prchal J (2007). Is Hematopoiesis Clonal in Healthy Elderly Females? [Abstract]. Blood, 2007; 110 (11): abstract 2243, 110(11), abstract 2243.
- Agarwal N, Swierczek S, Naidoo K, Prchal JT, Coetzer TL (2007). A novel Mutation of the aSpectrin Gene in a Family of Northern European Descent is Associated with Three Different Phenotypes. [Abstract]. Blood. 2007; 110 (11): abstract 1717.
- Spahr JE, Agarwal N, Rodgers GM (2007). Treatment of Immune-Mediated Thrombocytopenia Purpura with Concurrent IVIg and Platelet Transfusion: A Retrospective Review of 40 Patients. [Abstract]. Blood "Supplement", 108(11), A1598.
- Agarwal AM, Agarwal N, Tryka AF, Ward JH, Lim MS (2007). Blastic Transformation of Follicular lymphoma. [Abstract]. Archives of Pathology and Laboratory Medicine (supplement), September 2007.
- Agarwal N, Mojica-Henshaw MP, Kutlar F, Gaikwad A, Ou CN, Kutlar A, Prchal JT (2006). Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G->C) Leads to Undetectable Transcript and Mutant Peptide. [Abstract]. Blood (supplement), 2006; 108: A1598.
- Wada D, Agarwal N, Florell SR, Lim M (2006). Recurrent Squamous cell carcinoma and fallicular lymphoma arising in the scalp two years after treatment for lymphoma. [Abstract]. Arch Pathol Lab Med, 130, 1362-1403 (P14).
Video/Film/CD/Web/Podcast
- Agarwal N (2019). Why I Attend. 2019 Genitourinary Oncology Symposium (GU ASCO) https://dailynews.ascopubs.org/do/10.5555/ADN.19.190070/full/ [Web]. San Francisco, CA.
- Gill DM, Agarwal N (2018). Updates in the rapidly changing treatment landscape of metastatic renal cell carcinoma. ASCO daily news “expert commentary” [Web]. Available: https://goo.gl/T9n1Gi.
- Agarwal N (2016). Vaccine Therapy in Metastatic Renal Cell Carcinoma: Past, Present, and Future. ASCO Post. [Web]. Available: http://goo.gl/CqKjqd.
- Agarwal N (2016). Newly Diagnosed Metastatic Prostate Cancer Patient. [Web]. Available: http://goo.gl/x4aGWO.
- Agarwal N (2016). Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design, Journal of Clinical Oncology [Podcast]. Available: https://goo.gl/YE04QE.
- Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments [Web]. Immunotherapy. Available: https://goo.gl/pNFqvI.
- Agarwal N (2014). Perspective opinion on “Gleason score associated with time to development of neuroendocrine prostate cancer [Web]. Available: https://goo.gl/eKj1Q1.
- Wada D, Agarwal N, Lim M (2005). Case of the Quarter: Society of Hematopathology [Web]. Society for Hematopathology. Available: http://www.sh-eahp.org/.
- Hussain I, Agarwal N (2003). DRESS syndrome associated with cephalosporin therapy [Web]. E-Letter in British Medical Journal. Available: https://goo.gl/NIq711.
Global Impact
Education History
| Professional Medical | All India Institute of Medical Sciences Medicine M.D. |
| Professional Medical | Assam Medical College Medicine M.B.B.S. |